Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors

Globe Newswire 19-Feb-2025 6:00 PM

NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Septerna, Inc. ("Septerna" or the "Company") (NASDAQ:SEPN). The investigation concerns whether Septerna and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

On February 18, 2025, Septerna announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786, an oral small molecule PTH1R agonist for treating hypoparathyroidism, in healthy volunteers. Septerna stated that this decision was based on the observation of two unexpected severe (Grade 3) cases of elevated unconjugated bilirubin in the MAD portion of the trial, both occurring without corresponding increases in ALT, AST, or GGT liver enzyme levels. On this news, the price of Septerna shares declined by $6.09 per share, or approximately 46%, from $12.96 per share on February 14, 2025, to close at $6.87 on February 18, 2025.

If you purchased or otherwise acquired Septerna securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out the form below to discuss your rights or interests with respect to these matters without any cost to you.

[CONTACT US]

Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com